POR CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
Por um escritor misterioso
Descrição
CVM-1118 (foslinanib) is a phosphoric ester compound selected from 2-phenyl-4-quinolone derivatives. The NCI 60 cancer panel screening showed CVM-1125, the major active metabolite of CVM-1118, to exhibit growth inhibitory and cytotoxic effects at nanomolar range. CVM-1118 possesses multiple bioactivities, including inducing cellular apoptosis, cell cycle arrest at G2/M, as well as inhibiting vasculogenic mimicry (VM) formation. The TNF receptor associated protein 1 (TRAP1) was identified as the binding target of CVM-1125 using nematic protein organization technique (NPOT) interactome analysis. Further studies demonstrated CVM-1125 reduced the protein level of TRAP1 and impeded its downstream signaling by reduction of cellular succinate levels and destabilization of HIF-1α. The pharmacogenomic biomarkers associated with CVM-1118 were also examined by Whole Genome CRISPR Knock-Out Screening. Two hits (STK11 and NF2) were confirmed with higher sensitivity to the drug in cell knock-down experiments. Biological assays indicate that the mechanism of action of CVM-1118 is via targeting TRAP1 to induce mitochondrial apoptosis, suppress tumor cell growth, and inhibit vasculogenic mimicry formation. Most importantly, the loss-of-function mutations of STK11 and NF2 are potential biomarkers of CVM-1118 which can be applied in the selection of cancer patients for CVM-1118 treatment. CVM-1118 is currently in its Phase 2a clinical development.
Tumor cell vascular mimicry: Novel targeting opportunity in melanoma. - Abstract - Europe PMC
PDF) CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1
HSP 75 Antibody (TR1) SCBT - Santa Cruz Biotechnology
Effect of evodiamine on ABCA1 transcription and the degradation rate of
POR Tumor subtypes and signature model construction based on chromatin regulators for better prediction of prognosis in uveal melanoma
POR Case Report: Brainstem angiocentric glioma presenting in a toddler child–diagnostic and therapeutic challenges
PDF) CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1
Molecules, Free Full-Text
Evodiamine enhances apo A1-mediated ChE from THP-1 macrophages and
Antitumor Agents. 211. Fluorinated 2-Phenyl-4-quinolone Derivatives as Antimitotic Antitumor Agents
TRAP1 activity in tumor cell mitochondria. (A) TRAP1 inhibits oxidative
Relationship between complex size and essentiality. a, fraction of
HIF-1α is required for the growth and survival of LKB1-deficient cells
POR CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1
Kuan-Tin Chen's research works China Medical University Hospital, Taichung (CMUH) and other places
de
por adulto (o preço varia de acordo com o tamanho do grupo)
